Related Experiment Videos
Increased serum phospholipids in epileptic children treated with phenobarbitone
Journal of Neurology, Neurosurgery, and Psychiatry
|January 1, 1982
Summary
Phenobarbitone treatment in epileptic children increased phospholipids in blood and lipoproteins. Sodium valproate showed no significant changes in lipid profiles or lipolytic activity.
Area of Science:
- Biochemistry
- Pediatric Neurology
- Pharmacology
Background:
- Epilepsy is a common neurological disorder in children.
- Anticonvulsant medications like phenobarbitone and sodium valproate are standard treatments.
- Understanding the metabolic effects of these drugs is crucial for patient management.
Purpose of the Study:
- To evaluate the effects of phenobarbitone and sodium valproate on plasma lipid concentrations.
- To assess the impact of these antiepileptic drugs on post-heparin lipolytic activity in children.
Main Methods:
- Twenty-two epileptic children were included in the study.
- Participants were treated with either phenobarbitone or sodium valproate.
- Plasma lipid profiles and post-heparin lipolytic activity were measured.
Main Results:
- Phenobarbitone treatment led to increased phospholipid levels in whole blood, LDL, and HDL.
- No significant changes in lipid concentrations were observed in children treated with sodium valproate.
- A slight, non-statistically significant increase in enzyme activities was noted in both treatment groups compared to controls.
Conclusions:
- Phenobarbitone may alter lipid metabolism, specifically phospholipid levels, in epileptic children.
- Sodium valproate appears to have a neutral effect on lipid profiles and lipolytic activity in this pediatric population.
- Further research is warranted to explore the long-term metabolic consequences of phenobarbitone therapy.